

Insight Genetics and VICC partnership, 5/14

May 2014—Insight Genetics is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to identify genetic markers that will help select the targeted therapeutics most effective for each triple-negative breast cancer patient. The company will work with Jennifer Pietenpol, PhD, director of VICC, and the laboratory group at VICC, and will focus on identifying novel genetic drivers for six distinct subtypes of triple-negative breast cancers (identified by work from the Pietenpol laboratory and published in the Journal of Clinical Investigation). The work is also designed to identify new TNBC biomarkers and develop assays based on these biomarkers.

[Insight Genetics](#), 615-255-8880